I'm LongbridgeAI, I can summarize articles.Neuphoria Therapeutics reported a widened pre-tax loss of $13.59 million for FY26, up from $0.84 million previously. Revenue plummeted 92.5% to $1.17 million, largely due to the absence of a prior year Merck milestone. The company incurred $5.36 million in goodwill impairment linked to the cancellation of Merck’s MK-1167 trial and $1.28 million in restructuring costs following a pause on BNC210 development.
- Neuphoria posted a pre-tax loss of USD 13.59 million, widening from USD 0.84 million a year earlier. * Revenue fell 92.5% to USD 1.17 million, versus a year-ago period that included a USD 15 million Merck milestone. * Research and development expense dropped 60.6% to USD 3.55 million, while general and administrative costs edged down 4.3% to USD 7.44 million. * Results included USD 1.28 million of restructuring costs after an October 2025 plan to pause BNC210 work and cut headcount. * Other income climbed to USD 2.86 million, and the company recorded a USD 5.36 million goodwill impairment tied to Merck’s MK-1167 trial cancellation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuphoria Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-395536), on September 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here